## Abstract No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measu
Evaluation of a screening instrument for essential tremor
✍ Scribed by Delia Lorenz; Frank Papengut; Henrik Frederiksen; Florian Kopper; Stephan Klebe; Kaare Christensen; Stefan Schreiber; Günther Deuschl
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 119 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
To evaluate a screening instrument for essential tremor (ET) consisting of a seven‐item questionnaire and a spiral drawing. A total of 2,448 Danish twins aged 70 years or more and a second sample aged 60 years or more (n = 1,684) from a population‐based northern German cross‐sectional study (PopGen ET) were screened for ET. Inclusion criteria were a previous diagnosis of ET, a positive answer to two or more questions of the questionnaire or a spiral rating >4 (range of scale 0–9). Three hundred thirteen of 380 positively screened and 321 negatively screened subjects were clinically examined. Definite or probable ET was diagnosed in 104 patients, possible in 86 and other tremors in 98 patients. The sensitivity of the screening instrument was 70.5%, the positive predictive value was 64.9%, the specificity was 68.2%, and the negative predictive value was 73.5%. Tremor severity correlated significantly with higher spiral scores and more positive items. More patients were identified by spiral drawing in all tremor groups. The interrater and intrarater reliability for spirals ranged from 0.7 to 0.8 using intraclass coefficient. A cluster analysis revealed that the questionnaire can be reduced to three items, about uncontrollable tremor in any body part, tremor while drinking or pouring and other family members with tremor, without loosing efficacy. We present an easy to use and reliable screening instrument that is effective to identify patients with ET but not able to exclude patients with other tremor forms. © 2008 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract In this evaluator‐blinded open‐treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12‐week exten
## Abstract Fragile X‐associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder, was described recently among male carriers of expanded alleles (55–200 CGG repeats; premutation range) of the fragile X mental retardation 1 (__FMR1__) gene. Major features of the syndrome include intenti
We read with interest the recent article by Handforth and Martin, 1 "Pilot Efficacy and Tolerability: A Randomized, Placebo-Controlled Trial of Levetiracetam for Essential Tremor." We also performed a pilot study of levetiracetam (LEV, Keppra) for essential tremor (ET) in 6 ET patients to assess its
We conducted a double-blind trial of isoniazid in 11 patients with essential tremor and four patients with other types of postural action tremor. The tremor had not been helped by beta-blockers or primidone. Isoniazid was given in doses up to 1,200 mg daily, together with 100 mg pyridoxine, for four